Formoterol Fumarate

"Formoterol Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Descriptor ID	D000068759
MeSH Number(s)	D02.033.100.291.425 D02.092.063.291.425
Concept/Terms	Formoterol Fumarate Formoterol Fumarate Formoterol Fumarate, ((R,R)-(+-))-isomer 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate BD 40A BD 40A Formoterol Formoterol Eformoterol Oxis Oxis Arformoterol Arformoterol Formoterol, ((R,R)-(+-))-isomer Foradil Foradil

Below are MeSH descriptors whose meaning is more general than "Formoterol Fumarate".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Alcohols [D02.033]
Amino Alcohols [D02.033.100]
Ethanolamines [D02.033.100.291]
Formoterol Fumarate [D02.033.100.291.425]
Amines [D02.092]
Amino Alcohols [D02.092.063]
Ethanolamines [D02.092.063.291]
Formoterol Fumarate [D02.092.063.291.425]

Below are MeSH descriptors whose meaning is related to "Formoterol Fumarate".

Below are MeSH descriptors whose meaning is more specific than "Formoterol Fumarate".

Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Mometasone Furoate, Formoterol Fumarate Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Formoterol Fumarate" by people in this website by year, and whether "Formoterol Fumarate" was a major or minor topic of these publications.

Bar chart showing 19 publications over 9 distinct years, with a maximum of 5 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2016	2	0	2
2017	2	0	2
2018	1	0	1
2019	1	0	1
2020	3	1	4
2021	2	3	5
2022	0	2	2
2025	1	0	1

Below are the most recent publications written about "Formoterol Fumarate" by people in Profiles.

Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025 Feb; 211(2):205-214.

View in: PubMed
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022; 17:3061-3073.

View in: PubMed
Singh D, Rabe KF, Martinez FJ, Kr?ll M, Jenkins M, Patel M, Dorinsky P. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022 06; 197:106857.

View in: PubMed
Chipps BE, Murphy KR, Oppenheimer J. 2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges. J Allergy Clin Immunol Pract. 2022 01; 10(1S):S19-S30.

View in: PubMed
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M, Darken P, Aurivillius M, Dorinsky P. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021 Aug-Sep; 185:106509.

View in: PubMed
Martinez FJ, Darken P, Dorinsky P. Reply to L?pez-Campos et al. and to Rogliani and Calzetta. Am J Respir Crit Care Med. 2021 04 01; 203(7):927-928.

View in: PubMed
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, Rossman K, St Rose E, Trivedi R, Ballal S, Darken P, Aurivillius M, Reisner C, Dorinsky P. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021 03 01; 203(5):553-564.

View in: PubMed
Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C. Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021; 16:179-189.

View in: PubMed
Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, Aurivillius M, Dorinsky P. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021 Jan-Dec; 15:17534666211034329.

View in: PubMed
Tervonen T, Martinez FJ, Hanania NA, Heidenreich S, Eudicone JM, Gilbert I. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.

View in: PubMed

People

Explore

Similar Concepts

Top Journals